Related Experiment Videos
Improving success rates for lead generation using affinity binding technologies
Gergely M Makara1, John Athanasopoulos
1Merck Research Laboratories, Merck & Co., RY80Y-325, Rahway, New Jersey 07065, USA. gergely_makara@merck.com
Current Opinion in Biotechnology
|November 1, 2005
Summary
Affinity technologies are revolutionizing drug discovery by enabling efficient detection of ligand-macromolecule interactions. These powerful methods are increasingly used for target identification and lead optimization, accelerating the development of new medicines.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Pharmacology
Background:
- Affinity technologies are crucial tools in modern drug discovery.
- Their application spans target identification, purification, and preclinical candidate selection.
- Detection of ligand-macromolecule interactions is a key area of study.
Purpose of the Study:
- To highlight the utility and impact of affinity technologies in drug discovery.
- To showcase recent advancements and emerging applications of these methods.
- To emphasize their role in addressing challenging targets and medicinal chemistry tasks.
Main Methods:
- Application of affinity technologies across various stages of drug discovery.
- Utilizing primary affinity screens for large libraries of small molecules and fragments.
- Employing affinity methods in secondary assays for medicinal chemistry optimization.
Main Results:
- Affinity methods have demonstrated significant utility in identifying drug leads.
- Primary screens are yielding results for previously challenging biological targets.
- Secondary assays using affinity techniques are providing new solutions for medicinal chemistry.
Conclusions:
- Affinity technologies are powerful and increasingly vital for efficient drug discovery.
- These methods facilitate the identification of drug candidates and optimize medicinal chemistry efforts.
- Continued development and application of affinity technologies promise to accelerate the discovery of novel therapeutics.